REG - AstraZeneca PLC - Change in ADS ratio <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

16/07/2015 12:53

RNS Number : 3556R
AstraZeneca PLC
26 June 2015
AstraZeneca PLC - Change in ADS ratio
AstraZeneca PLC (the "Company") today announces an intended ratio change to its NYSE-listed sponsored Level 2 American Depositary Receipt ("ADR") programme. The current ratio is one (1) American Depositary Share ("ADS") per one (1) Ordinary Share. The new ratio will be two (2) ADSs per one (1) Ordinary Share. The expected effective date for the ratio change is 27 July 2015. There will be no change to the underlying Ordinary Shares.
ADS holders at the close of business New York time on the record date, 22 July 2015, will receive a distribution of one additional ADS for every ADS held. The new ADSs are expected to be distributed on 24 July 2015. No action is required by ADS holders to effect this change.
Contact details for Citibank, N.A., the Company's ADR depositary, can be found below.
A C N Kemp
Company Secretary
26 June 2015
CONTACT
Citibank Shareholder Services
PO Box 43077
Providence
RI 02940-3077
US
Tel (toll free in the US): +1-888-697-8018
Tel (outside the US): +1-781-575-4555
Media Enquiries
Esra Erkal-Paler
+44 20 7604 8030 (UK/Global)
Jacob Lund 
+46 8553260 20 (Sweden)
Michele Meixell
+ 1 302 885 6351 (US)
Investor Enquiries
UK



Thomas Kudsk Larsen

+44 20 7604 8199
mob: +44 7818 524185
Eugenia Litz
Respiratory, Inflammation and Autoimmunity
+44 20 7604 8233
mob: +44 7884 735627
Nick Stone
Cardiovascular and
Metabolic Disease
+44 1763 263 994
mob: +44 7717 618834
Karl Hrd
Oncology
+44 20 7604 8123
mob: +44 7789 654364
Craig Marks
Infection, Neuroscience and Gastrointestinal Disease
+44 20 7604 8591
mob: +44 7881 615764
Christer Gruvris

+44 20 7604 8126
mob: +44 7827 836825
US



Dial / Toll-Free

301-398-3251
866-381-7277

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCLLFFIRIIRFIE